US President Donald Trump Imposes 100% Tariffs on Branded and Patented Medicine Imports
U.S. President Donald Trump has announced 100% tariffs on branded and patented medicines, effective October 1, to weaponize access to healthcare. While a 15% cap exists for the EU and Japan, hubs like the U.K., Switzerland, and Singapore face the full burden. India’s generics industry is currently spared, but uncertainty remains over Active Pharmaceutical Ingredients (APIs) and future expansions to biosimilars. This move could significantly raise drug costs for American patients and disrupt global supply chains, forcing nations like India to diversify export markets and accelerate alternative trade alliances to maintain pharma sector growth.
Key Points
- The U.S. is imposing 100% tariffs on imported branded and patented medicines to reshape global supply chains.
- India's generics industry, which accounts for 90% of U.S. prescriptions, is currently exempt but remains vulnerable to future tariff expansions.
- There is significant uncertainty regarding whether Active Pharmaceutical Ingredients (APIs), dominated by India and China, will be included in the tariff net.
- The move is expected to increase annual drug costs in the U.S. by approximately $51 billion, according to an Ernst & Young study.
Exam Facts
- Tariffs on branded and patented medicines are set to take effect from October 1.
- India exported more than $10.5 billion worth of formulations to the U.S. in FY25.
- Generics account for 90% of prescriptions dispensed in the U.S. but only 13% of total spending.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.